CN1863773A - 四氢吡啶衍生物 - Google Patents

四氢吡啶衍生物 Download PDF

Info

Publication number
CN1863773A
CN1863773A CNA2004800293878A CN200480029387A CN1863773A CN 1863773 A CN1863773 A CN 1863773A CN A2004800293878 A CNA2004800293878 A CN A2004800293878A CN 200480029387 A CN200480029387 A CN 200480029387A CN 1863773 A CN1863773 A CN 1863773A
Authority
CN
China
Prior art keywords
phenyl
heteroaryl
chloro
general formula
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800293878A
Other languages
English (en)
Chinese (zh)
Inventor
奥利维尔·贝曾康
蒂埃里·西费朗
丹尼尔·比尔
瓦尔特·菲施利
托马斯·韦勒
尤博斯·雷门
西尔维娅·理查德-比洛斯泰恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN1863773A publication Critical patent/CN1863773A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800293878A 2003-10-09 2004-10-05 四氢吡啶衍生物 Pending CN1863773A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0311146 2003-10-09
EPPCT/EP03/11146 2003-10-09

Publications (1)

Publication Number Publication Date
CN1863773A true CN1863773A (zh) 2006-11-15

Family

ID=34486009

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800293878A Pending CN1863773A (zh) 2003-10-09 2004-10-05 四氢吡啶衍生物

Country Status (6)

Country Link
US (1) US20080234305A1 (enExample)
JP (1) JP2007508260A (enExample)
CN (1) CN1863773A (enExample)
AU (1) AU2004283814A1 (enExample)
CA (1) CA2540543A1 (enExample)
WO (1) WO2005040120A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101696187B (zh) * 2009-09-30 2011-09-07 徐州工业职业技术学院 N-取代基-1,2,3,6-四氢吡啶的合成方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2577084A1 (en) * 2004-08-25 2006-03-02 Olivier Bezencon Bicyclononene derivatives as renin inhibitors
GB0500784D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
CA2615048A1 (en) * 2005-07-22 2007-01-25 Merck Frosst Canada Ltd. Renin inhibitors
JP5306821B2 (ja) 2005-12-30 2013-10-02 ノバルティス アーゲー レニン阻害剤としての３，５−置換ピペリジン化合物
CA2642424A1 (en) * 2006-03-03 2007-09-07 Actelion Pharmaceuticals Ltd. Primary amines as renin inhibitors
NZ571595A (en) * 2006-03-08 2010-06-25 Actelion Pharmaceuticals Ltd New amines
EP1908471A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors
AU2008253519A1 (en) 2007-05-24 2008-11-27 Merck Frosst Canada Ltd Novel case of renin inhibitors
NZ582098A (en) 2007-06-25 2012-03-30 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
EP2190811B1 (en) 2007-08-20 2013-08-07 Merck Canada Inc. Renin inhibitors
WO2009071448A1 (en) 2007-12-05 2009-06-11 Basf Se Pyridylmethyl-sulfonamide compounds
KR101247840B1 (ko) 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
US8889714B2 (en) 2008-05-05 2014-11-18 Actelion Pharmaceuticals Ltd. 3,4-substituted piperidine derivatives as renin inhibitors
JP5502089B2 (ja) 2008-10-09 2014-05-28 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
CN102209537A (zh) 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
WO2010090875A1 (en) 2009-01-21 2010-08-12 Rigel Pharmaceuticals, Inc. Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
WO2012066488A2 (en) 2010-11-17 2012-05-24 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
KR100879647B1 (ko) * 2000-03-06 2009-01-20 아카디아 파마슈티칼스 인코포레이티드 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물
US20030013883A1 (en) * 2000-06-16 2003-01-16 Tamagnan Gilles D. Tropane analogs binding to monoamine transporters
KR100783863B1 (ko) * 2002-04-29 2007-12-10 액테리온 파마슈티칼 리미티드 7-아릴-3,9-디아자바이사이클로(3.3.1)논-6-엔 유도체 및고혈압, 심혈관 질환 또는 신장 질환의 치료에서 레닌저해물질로써 이들의 용도
MXPA04012136A (es) * 2002-06-27 2005-04-19 Actelion Pharmaceuticals Ltd Nuevos derivados de tetrahidropiridina como inhibidores de renina.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101696187B (zh) * 2009-09-30 2011-09-07 徐州工业职业技术学院 N-取代基-1,2,3,6-四氢吡啶的合成方法

Also Published As

Publication number Publication date
WO2005040120A1 (en) 2005-05-06
CA2540543A1 (en) 2005-05-06
AU2004283814A1 (en) 2005-05-06
JP2007508260A (ja) 2007-04-05
US20080234305A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
CN1273451C (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
CN1310917C (zh) 趋化因子受体活性的四氢吡喃基环戊基四氢吡啶并吡啶调节剂
CN1028103C (zh) 哌啶基苯并咪唑类化合物的制备方法
CN1802376A (zh) Cgrp受体拮抗剂
CN1662530A (zh) 具有dpp－iv抑制活性的氮杂二环辛烷与壬烷衍生物
CN1426411A (zh) 3－(二芳基亚甲基)－8－氮杂双环[3.2.1]辛烷衍生物
CN1780663A (zh) 作为肾素抑制剂的新型3－位具有杂原子的9－氮杂双环壬烯衍生物
JP2010527942A (ja) 新規類のレニン阻害剤
CN1890239A (zh) 二氮杂二环壬烯及带有新的侧链的四氢吡啶衍生物
CN1349524A (zh) 血管紧张肽原酶抑制剂
US20080234305A1 (en) Novel Tetrahydropyridine Derivatives
CN1780836A (zh) 作为血管紧张肽原酶抑制剂的新型二氮杂双环壬烯和四氢吡啶衍生物
CN1780837A (zh) 新型氮杂二环壬烯衍生物
CN1780838A (zh) 新型二氮杂双环壬烯衍生物
CN1798744A (zh) 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物
CN1097006A (zh) O-芳基吗啡喃的醚类化合物
JP2012511514A (ja) レニン阻害剤としての３，４−置換ピペリジン誘導体
CN1867568A (zh) 二氮杂二环壬烯衍生物及其作为血管紧张肽原酶抑制剂的用途
CN1780833A (zh) 托品烷衍生物及其作为血管紧张肽转化酶抑制剂的应用
CN1897941A (zh) 趋化因子受体活性的烷基氨基、芳基氨基以及氨磺酰基环戊基酰胺调节剂
KR100963455B1 (ko) 신규한 피페리딘 카르복실산 아미드 유도체
CN1103402A (zh) 取代的吡咯类化合物
CN1909906A (zh) 作为趋化因子受体活性调节剂的2,6－二取代的哌啶类化合物
CN1167682C (zh) 毒蕈碱拮抗剂
CN1311785A (zh) 作为甘氨酸拮抗剂的四氢喹啉衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication